Covishield vaccine update: Serum Institute gets DCGI nod for manufacture of Oxford-AstraZeneca Covid-19 vaccine

By: |
New Delhi | Updated: Jan 04, 2021 11:22 AM

Covishield vaccine update: The Covishield has a shelf life of six months when stored at 2 degree celsius to 8 degree celsius.

The consignment for Mumbai will leave by road. Trucks belonging to Kool-ex Cold Chain Ltd are being used to ferry the vaccine stocks from Serum Institute.The consignment for Mumbai will leave by road. Trucks belonging to Kool-ex Cold Chain Ltd are being used to ferry the vaccine stocks from Serum Institute.

Covishield vaccine update: Drugs Controller General of India (DCGI) has granted permission to Serum Institute of India to manufacture the ‘Covishield’ Covid-19 vaccine. The approval has been granted for active immunization of persons aged 18 years or above against the Coronavirus. The DCGI has stated that the second dose of Covishield must be administered between four to six weeks after the inoculation of the first dose. However, data ascertained from overseas studies have disclosed that a second dose can be administered up to 12 weeks after the first dose, the DCGI said in a statement.

The Covishield has a shelf life of six months when stored at 2 degree celsius to 8 degree celsius. Once opened, multi-dose vials must be used within 6 hours when stored between 2 degree celsius to 8 degree celsius, the DCGI said.

The Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) met on January 1 and January 2 and made recommendations in respect of the proposal for Restricted Emergency Approval of COVID-19 virus vaccine of Serum Institute of India (SII). SII has presented a Recombinant Chimpanzee Adenovirus vector vaccine Covishield encoding the SARS-CoV-2 Spike (S) glycoprotein with technology transfer from Oxford-AstraZeneca.

Covishield Efficacy

The firm submitted safety, immunogenicity, and efficacy data generated on 23,745 participants aged 18 years or older from overseas clinical studies. The overall vaccine efficacy was found to be 70.42 per cent. Further, the SII was granted permission to conduct Phase 2 and Phase 3 clinical trials on 1,600 participants within India. The firm also submitted the interim safety and immunogenicity data generated from this trial and the data was found comparable with the data from the overseas clinical studies. After detailed deliberations, the Subject Expert Committee has recommended the grant of permission for restricted use in an emergency situation subject to certain regulatory conditions. The clinical trial ongoing within the country by the firm will continue.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19 vaccination in India: Over 20 lakh beneficiaries inoculated
2Covid-19 vaccine update: EU demands that vaccine makers honour their commitments
3COVID-19 in Delhi: 157 fresh cases, positivity rate slips to 0.24%